• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Abbott still looking to pull Xience DES from Indian market

September 11, 2017 By Fink Densford

AbbottAbbott (NYSE:ABT) is still looking to pull its Xience Alpine drug-eluting stent from the Indian marketplace after the country’s regulatory body set significant price caps on stents earlier this year, according to an Indian Economic Times report.

The company reportedly approached India’s National Pharmaceutical Pricing Authority looking to withdraw the Xience stent yet again due to caps, along with its Absorb, which it announced it was pulling from the global marketplace late last week.

“We applied for Alpine withdrawal back in April and the application was rejected. We continue to remain engaged with the NPPA to determine the way forward for Alpine in India,” an Abbott spokesperson told ET, according to the report.

The NPPA rejected the previous application from Abbott to withdraw its stents, as well as an application from Medtronic (NYSE:MDT), which was also looking to pull its high-value stents from the Indian market in light of the price caps.

The companies were ordered to maintain their supply of the stents for 6 months – a period which ended in August, according to the Economic Times.

If the new application is approved by the NPPA, it could pave the way for other major companies to pull their advanced stents from the market, according to the report.

Earlier this year, Abbott, Medtronic and Boston Scientific said they planned to tell Indian officials that any further price control measures would risk future investments and make them less likely to introduce new products to the region.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS